Myasthenia gravis: Immunopathogenesis, diagnosis, and management

CONTINUUM Lifelong Learning in Neurology

Volumn 15, Issue 1, 2009, Pages 35-62

  Meriggioli, Matthew N ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMBENONIUM; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CHOLINERGIC RECEPTOR ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EDROPHONIUM CHLORIDE; ENZYME ANTIBODY; IMMUNOGLOBULIN; MUSCLE SPECIFIC RECEPTOR TYROSINE KINASE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEOSTIGMINE; NEOSTIGMINE METHYL SULFATE; PREDNISONE; PYRIDOSTIGMINE; RITUXIMAB; TACROLIMUS; UNCLASSIFIED DRUG; VITAMIN D;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BRADYCARDIA; BRONCHUS SECRETION; CASE REPORT; CATARACT; CORTICOSTEROID INDUCED MYOPATHY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG INHIBITION; DRUG MEGADOSE; DYSPHAGIA; ELECTROMYOGRAM; FEMALE; FLUID RETENTION; GINGIVA HYPERPLASIA; GLAUCOMA; GROWTH INHIBITION; HEMORRHAGIC CYSTITIS; HIRSUTISM; HUMAN; HYPERTENSION; IMMUNOASSAY; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; IMPAIRED GLUCOSE TOLERANCE; LEUKOPENIA; LIVER TOXICITY; LYMPHOMA; MALE; MELANOMA; MUSCLE CRAMP; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NAUSEA; NEPHROTOXICITY; NERVE STIMULATION; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROLOGIC EXAMINATION; OBESITY; OSTEOPOROSIS; PARESTHESIA; PEPTIC ULCER; PLASMAPHERESIS; POTASSIUM DEPLETION; PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SIDE EFFECT; SKELETAL MUSCLE; SODIUM RETENTION; SWEATING; THYMECTOMY; THYMUS; TREMOR; VOMITING;

EID: 77953545405     PISSN: 10802371     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.CON.0000300007.56974.b7     Document Type: Article

References (34)

1. Batocchi AP, Evoli A, Dischino C, et al. Therapeutic apheresis in myasthenia gravis. Ther Apher 2000;4(4):275-279.
2. Chan KH, Lachance DH, Harper CM, Lennon VA. Frequency of seronegativity in adult-acquired generalized myasthenia gravis. Muscle Nerve 2007;36(5):651-658.
3. Ciafaloni E, Nikhar NK, Massey JM, Sanders DB. Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology 2000;55(3):448-450.
4. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present and future. J Clin Invest 2006;116(11):2843-2854.
5. De Feo LG, Schottlender J, Martelli NA, Molfino NA. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve 2002;26(1):31-36.
6. Drachman DB, Jones RJ, Brodsky RA. Treatment of refractory myasthenia: "rebooting" with high-dose cyclophosphamide. Ann Neurol 2003;53(1):29-34.
7. Evoli A, Bianchi MR, Riso R, et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann NY Acad Sci 2008;1132:76-83.
8. Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003;126(pt 10):2304-2311.
9. Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2008;(1):CD002277.
10. Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve 2008;37(2):141-149.
11. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55(1): 7-15.
12. Hatanaka Y, Hemmi S, Morgan MB, et al. Nonresponsiveness to anticholinesterase agents in patients with MuSK-positive MG. Neurology 2005;65(9):1508-1509.
13. Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nature Medicine 2001;7(3):365-368.
14. Jani-Ascadi A, Lisak RP. Myasthenic crisis: guidelines for prevention and treatment. J Neurol Sci 2007;261(1-2):127-133.
15. Jaretski A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55(1): 16-23.
16. Juel VC, Massey JM. Myasthenia gravis. Orphanet J Rare Dis 2007;2:44.
17. Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 2004;29(4):484-505.
18. Kouyoumdjian JA, Stålberg EV. Reference jitter values for concentric needle electrodes in voluntarily activated extensor digitorum communis muscle and orbicularis oculi muscles. Muscle Nerve 2008;376):694-699.
19. Kupersmith MJ, Latknay R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol 2003;60(2):243-248.
20. Le Panse R, Cizeron-Clairac G, Cuvelier M, et al. Regulatory and pathogenic mechanisms in human autoimmune myasthenia gravis. Ann NY Acad Sci 2008;1132:135-142.
21. McConville J, Farrugia ME, Beeson D, et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004;55(4): 580-584.
22. Meriggioli MN, Ciafaloni E, Al-Hayk KA, et al. Mycophenolate mofetil in the treatment of myasthenia gravis: an analysis of efficacy, safety and tolerability. Neurology 2003;61(10):1438-1440.
23. Meriggioli MN, Sanders DB. Advances in the diagnosis of neuromuscular disorders. Am J Phys Med Rehabil 2005;84(8):627-638.
24. Nagane Y, Utsugisawa K, Obara D, et al. Efficacy of low-dose FK-506 in the treatment of myasthenia gravis-a randomized pilot study. Eur Neurol 2005;53(3): 146-150.
25. Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998;50(6):1778-1783.
26. Pascuzzi RM. The edrophonium test. Semin Neurol 2003;23(1):83-88.
27. Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984;15(3):291-298.
28. Phillips LH 2nd. The epidemiology of myasthenia gravis. Ann N Y Acad Sci 2003; 998:407-412.
29. Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology 2003;61(12):1652-1661.
30. Sanders DB, Siddiqui ZA. Lessons from two trials of mycophenolate mofetil in myasthenia gravis. Ann N Y Acad Sci 2008;1132:249-253.
31. Sathasivam S. Steroids and immunosuppressant drugs in myasthenia gravis. Nature Clin Pract Neurol 2008;4(6):317-327.
32. Seneviratne J, Mandrekar J, Wijdicks EF, Rabinstein AA. Noninvasive ventilation in myasthenic crisis. Arch Neurol 2008;65(1):54-58.
33. Tindall RS, Phillips JT, Rollins JA, et al. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci 1993;681:539-551.
34. Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 2007;68(11):837-841.